Summary
Small venotomies (a hole in the vein to provide access for surgical procedures) are routinely made and closed using manual compression. As venotomies get bigger it becomes more difficult to close them, leading to complications (blood loss, haematoma, infection and thrombosis). Developments in transcatheter heart valve procedures and left atrial appendage occlusion requires large venotomies in the femoral vein to gain access to the heart. These large venotomies are difficult to close, leaving patients exposed to additional complications, pain and discomfort. Hence, there is a strong unmet medical need for effective methods to close venotomies.
Vivasure Medical Limited is a Irish R&D performing medical device company, established in 2008 and secured a total of €45M funds. Vivasure developed the patented PerQseal platform technology as effective method for large arterial and venous closures. PerQseal Venous is the world’s first absorbable patch-based closure product for large venotomy closure (over 8 mm). By delivering an intra-venous patch without surgery, a surgeon can seal vessels from inside while providing a matrix to support wound healing. PerQseal Venous is largely based on Vivasure’s already existing and well-validated PerQseal®Arterial product, used to close arterial vessels and already in clinical use.
Following clinical validation and preparation for EU and US wide commercialisation in the VENOCLOSE project, Vivasure will target the large and ever-growing venous closure market. Vivasure has successfully obtained ISO13485 Certification and CE certification for its arterial closure device, which will pave the way for PerQseal Venous. The company will leverage existing customer-base among cardiologists and distribution partner, contributing to a further de-risking of PerQseal Venous commercialisation. Obtaining €2.5M in EIC-Accelerator funding will accelerate the road to market for PerQseal Venous, and lead to direct revenue and employment growth at Vivasure.
Vivasure Medical Limited is a Irish R&D performing medical device company, established in 2008 and secured a total of €45M funds. Vivasure developed the patented PerQseal platform technology as effective method for large arterial and venous closures. PerQseal Venous is the world’s first absorbable patch-based closure product for large venotomy closure (over 8 mm). By delivering an intra-venous patch without surgery, a surgeon can seal vessels from inside while providing a matrix to support wound healing. PerQseal Venous is largely based on Vivasure’s already existing and well-validated PerQseal®Arterial product, used to close arterial vessels and already in clinical use.
Following clinical validation and preparation for EU and US wide commercialisation in the VENOCLOSE project, Vivasure will target the large and ever-growing venous closure market. Vivasure has successfully obtained ISO13485 Certification and CE certification for its arterial closure device, which will pave the way for PerQseal Venous. The company will leverage existing customer-base among cardiologists and distribution partner, contributing to a further de-risking of PerQseal Venous commercialisation. Obtaining €2.5M in EIC-Accelerator funding will accelerate the road to market for PerQseal Venous, and lead to direct revenue and employment growth at Vivasure.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/946304 |
| Start date: | 01-05-2020 |
| End date: | 31-03-2023 |
| Total budget - Public funding: | 3 886 887,00 Euro - 2 499 999,00 Euro |
Cordis data
Original description
Small venotomies (a hole in the vein to provide access for surgical procedures) are routinely made and closed using manual compression. As venotomies get bigger it becomes more difficult to close them, leading to complications (blood loss, haematoma, infection and thrombosis). Developments in transcatheter heart valve procedures and left atrial appendage occlusion requires large venotomies in the femoral vein to gain access to the heart. These large venotomies are difficult to close, leaving patients exposed to additional complications, pain and discomfort. Hence, there is a strong unmet medical need for effective methods to close venotomies.Vivasure Medical Limited is a Irish R&D performing medical device company, established in 2008 and secured a total of €45M funds. Vivasure developed the patented PerQseal platform technology as effective method for large arterial and venous closures. PerQseal Venous is the world’s first absorbable patch-based closure product for large venotomy closure (over 8 mm). By delivering an intra-venous patch without surgery, a surgeon can seal vessels from inside while providing a matrix to support wound healing. PerQseal Venous is largely based on Vivasure’s already existing and well-validated PerQseal®Arterial product, used to close arterial vessels and already in clinical use.
Following clinical validation and preparation for EU and US wide commercialisation in the VENOCLOSE project, Vivasure will target the large and ever-growing venous closure market. Vivasure has successfully obtained ISO13485 Certification and CE certification for its arterial closure device, which will pave the way for PerQseal Venous. The company will leverage existing customer-base among cardiologists and distribution partner, contributing to a further de-risking of PerQseal Venous commercialisation. Obtaining €2.5M in EIC-Accelerator funding will accelerate the road to market for PerQseal Venous, and lead to direct revenue and employment growth at Vivasure.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
